Short answer
Eton Pharmaceuticals, Inc. (ETON) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $22M (up 117.5% year over year) with net income of −$2M.
Q3 2025 key financials · XBRL
- Revenue
- $22M
- +117.5% YoY · +18.7% QoQ
- Net income
- −$2M
- −407.3% YoY · +25.5% QoQ
- Operating margin
- -6.1%
- Gross margin
- 35.0%
- EPS (diluted)
- −$0.08
- −366.7% YoY · +11.1% QoQ
Source: XBRL data from the Eton Pharmaceuticals, Inc. (ETON) Q3 2025 10-Q on SEC EDGAR. USD.
Eton Pharmaceuticals, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $22.459M, up $12.135M YoY from $10.324M
- Gross profit $7.855M, up from $6.302M; gross margin 35.0% vs 61.0% YoY
- Best products ALKINDI SPRINKLE®, INCRELEX®, and GALZIN®; product-specific revenue not disclosed
- Cash $37.1M and operating cash flow $22.075M through September 30, 2025
- Management expects liquidity sufficient for at least twelve months; development spending and faster growth could accelerate capital depletion
Risk Factors
- No risk-factors section provided in submitted filing text
- No newly added or changed risk identified
- No regulatory, legal, operational, competitive, market, or financial risk disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Eton Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.